RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance…
